You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

~ Buy the JANUMET XR (metformin hydrochloride; sitagliptin phosphate) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR JANUMET XR


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for JANUMET XR

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00532935 ↗ MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066) Completed Merck Sharp & Dohme Corp. Phase 3 2008-01-26 A study to evaluate the efficacy and safety of MK0431A in comparison to a commonly used medication in patients with type 2 diabetes
NCT00684528 ↗ A Double-Blind, Randomized, Active-Comparator (Metformin) Controlled, Clinical Trial to Study the Efficacy and Safety of the Strategy to Start Patients With Type 2 Diabetes Mellitus on Janumetâ„¢ Compared to Metformin Unknown status Clalit Health Services Phase 3 2008-06-01 Comparison between the effectiveness of one anti-diabetic drug (Metformin, To combination of this drug and additional drug (Janufer), In the community setting.
NCT00684528 ↗ A Double-Blind, Randomized, Active-Comparator (Metformin) Controlled, Clinical Trial to Study the Efficacy and Safety of the Strategy to Start Patients With Type 2 Diabetes Mellitus on Janumetâ„¢ Compared to Metformin Unknown status Meir Medical Center Phase 3 2008-06-01 Comparison between the effectiveness of one anti-diabetic drug (Metformin, To combination of this drug and additional drug (Janufer), In the community setting.
NCT00993187 ↗ Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202) Completed Merck Sharp & Dohme Corp. Phase 4 2010-05-04 This study will assess the effect of sitagliptin/metformin FDC 50/1000 mg (Janumet®), MK-0431A) compared with the effect of glimepiride on hemoglobin A1c (HbA1c). The primary hypothesis is that after 30 weeks, sitagliptin/metformin FDC 50/1000 mg provides superior reduction in HbA1c (mean change from baseline) compared to glimepiride.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for JANUMET XR

Condition Name

Condition Name for JANUMET XR
Intervention Trials
Type 2 Diabetes Mellitus 6
Diabetes Mellitus, Type 2 6
Bioequivalence 4
Polycystic Ovary Syndrome 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for JANUMET XR
Intervention Trials
Diabetes Mellitus, Type 2 14
Diabetes Mellitus 10
Polycystic Ovary Syndrome 2
Body Weight 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for JANUMET XR

Trials by Country

Trials by Country for JANUMET XR
Location Trials
United States 9
Canada 5
Mexico 5
Israel 2
Germany 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for JANUMET XR
Location Trials
Colorado 1
California 1
Louisiana 1
Pennsylvania 1
Ohio 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for JANUMET XR

Clinical Trial Phase

Clinical Trial Phase for JANUMET XR
Clinical Trial Phase Trials
Phase 4 6
Phase 3 4
Phase 2 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for JANUMET XR
Clinical Trial Phase Trials
Completed 17
Recruiting 1
Terminated 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for JANUMET XR

Sponsor Name

Sponsor Name for JANUMET XR
Sponsor Trials
Merck Sharp & Dohme Corp. 9
Galenicum Health 4
Emory University 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for JANUMET XR
Sponsor Trials
Industry 16
Other 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.